BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 6672988)

  • 1. American cutaneous leishmaniasis: disappearance of amastigotes from lesions during antimonial therapy.
    Mayrink W; Raso P; Melo MN; Michalick MS; Magalhães PA; Williams P; da Costa CA; Dias M
    Rev Inst Med Trop Sao Paulo; 1983; 25(6):265-9. PubMed ID: 6672988
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
    Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
    J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successful intralesional treatment of leishmaniasis caused by Leishmania brasiliensis panamensis using glucantime].
    Solano E; Hidalgo H; Zeledón R
    Med Cutan Ibero Lat Am; 1984; 12(1):19-24. PubMed ID: 6376976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases.
    Costa JM; Marsden PD; Llanos-Cuentas EA; Netto EM; Carvalho EM; Barral A; Rosa AC; Cuba CC; Magalhães AV; Barreto AC
    J Trop Med Hyg; 1986 Dec; 89(6):319-23. PubMed ID: 3806749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
    Fernández OL; Diaz-Toro Y; Ovalle C; Valderrama L; Muvdi S; Rodríguez I; Gomez MA; Saravia NG
    PLoS Negl Trop Dis; 2014 May; 8(5):e2871. PubMed ID: 24853871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].
    Rezzano S; Armas JA; Moreno G; Scorza JV
    Acta Cient Venez; 1984; 35(5-6):394-403. PubMed ID: 6537698
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cutaneous leishmaniasis].
    Vion B
    Rev Med Suisse Romande; 1989 Jun; 109(6):443-9. PubMed ID: 2547241
    [No Abstract]   [Full Text] [Related]  

  • 8. Relative insensitivity of a Kenyan strain of Leishmania donovani to pentavalent antimony therapy in hamsters.
    Hanson WL; Waits VB; Hendricks LD; Hockmeyer WT; Davidson DE; Chapman WL
    J Parasitol; 1983 Apr; 69(2):446-7. PubMed ID: 6854484
    [No Abstract]   [Full Text] [Related]  

  • 9. Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria.
    Belazzoug S; Neal RA
    Trans R Soc Trop Med Hyg; 1986; 80(4):670-1. PubMed ID: 3544363
    [No Abstract]   [Full Text] [Related]  

  • 10. Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine.
    Botelho AC; Mayrink W; Oliveira RC
    Acta Trop; 2009 Nov; 112(2):143-8. PubMed ID: 19631187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].
    Bourée P; Anciaux ML; Taugourdeau P
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):607-10. PubMed ID: 3003657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
    Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
    J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid clearance of circulating Leishmania kinetoplast DNA after treatment of visceral leishmaniasis.
    Disch J; Oliveira MC; Orsini M; Rabello A
    Acta Trop; 2004; 92(3):279-83. PubMed ID: 15533299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of the indirect immunofluorescence test in the therapeutic follow-up of cutaneous leishmaniasis americana].
    de Souza WJ; Coutinho SG; Marzochi MC; de Toledo LM; Gottlieb MV
    Mem Inst Oswaldo Cruz; 1982; 77(3):247-53. PubMed ID: 6763131
    [No Abstract]   [Full Text] [Related]  

  • 15. Diffuse cutaneous leishmaniasis acquired in Peru.
    Franke ED; Lucas CM; Tovar AA; Kruger JH; De Rivera MV; Wignall FS
    Am J Trop Med Hyg; 1990 Sep; 43(3):260-2. PubMed ID: 2221221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of oriental sore diagnosed as pseudolymphoma cutis.
    Morsy TA; El-Nasr MS
    J Egypt Soc Parasitol; 1983 Dec; 13(2):485-9. PubMed ID: 6319506
    [No Abstract]   [Full Text] [Related]  

  • 17. Late cutaneous leishmaniasis.
    Hart M; Livingood CS; Goltz RW; Totonchy M
    Arch Dermatol; 1969 Apr; 99(4):455-8. PubMed ID: 5769330
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experimental chemotherapy in hamsters, using paromomycin against 2 isolates of Leishmania mexicana and Leishmania braziliensis].
    Rezzano S; Moreno G; Scorza JV
    Rev Cubana Med Trop; 1982; 34(1):34-45. PubMed ID: 6750713
    [No Abstract]   [Full Text] [Related]  

  • 19. Pentavalent antimonial treatment in mucosal leishmaniasis.
    Sampaio RN; Sampaio JH; Marsden PD
    Lancet; 1985 May; 1(8437):1097. PubMed ID: 2860306
    [No Abstract]   [Full Text] [Related]  

  • 20. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
    Chapman WL; Hanson WL; Alving CR; Hendricks LD
    Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.